Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-12-28

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00417053

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-12-13

Last Posted Date: 2013-08-07

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 642

Registration Number: NCT00410631

Locations: 🇩🇪
Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
🇩🇪
Klinikum Dortmund, Dortmund, Germany
🇩🇪
Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany

and more 74 locations

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Myeloma

Interventions: Drug: Busulfan
Drug: Gemcitabine
Drug: Melphalan
Other: Hematopoietic Cell Transplantation
Drug: Rituximab for Patients with B-Cell Malignancies
Drug: Palifermin

First Posted Date: 2006-12-13

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 145

Registration Number: NCT00410982

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Prednisone
Drug: Melphalan
Drug: Thalidomide
Drug: Defibrotide

First Posted Date: 2006-12-04

Last Posted Date: 2016-05-10

Lead Sponsor: Silvio Aime

Target Recruit Count: 24

Registration Number: NCT00406978

Locations: 🇮🇹
Div. Univ. Di Ematologia, Az. Osp. San Giovanni Battista, Torino, TO, Italy
🇮🇹
Dip. Scienze Mediche & IRCAD-Università, UDA Ematologia, Novara, Italy
🇮🇹
Servizio di Ematologia, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy

and more 2 locations

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Phase 3

Completed

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: Melphalan
Drug: Prednisone
Drug: Aspirin
Drug: Placebo

First Posted Date: 2006-11-30

Last Posted Date: 2017-01-11

Lead Sponsor: Celgene Corporation

Target Recruit Count: 459

Registration Number: NCT00405756

Locations: 🇦🇹
University Hospital Innsbruck, Innsbruck, Austria
🇧🇾
Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology, Gomel, Belarus
🇧🇪
AZ St-Jan Brugge Oostende AV, Brugge, Belgium

and more 94 locations

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: ibritumomab tiuxetan
Drug: rituximab
Drug: melphalan
Drug: vinorelbine tartrate / G-CSF
Procedure: autologous hematopoietic stem cell harvesting and transplantation

First Posted Date: 2006-10-26

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 20

Registration Number: NCT00392691

Locations: 🇨🇭
Saint Claraspital AG, Basel, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Kantonsspital Liestal, Bern, Switzerland

and more 7 locations

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-10-17

Last Posted Date: 2011-01-11

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 60

Registration Number: NCT00388635

Locations: 🇪🇸
Clínica Universitaria de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Clínico San Carlos de Madrid, Madrid, Spain
🇪🇸
Hospital Doce de Octubre, Madrid, Spain

and more 15 locations